Israel-based RedHill Biopharma enrolled the last patient into its phase II study of Bekinda 12 mg.
Bekinda is an irritable bowel syndrome with diarrhea treatment.
Here's what you should know.
1. Researchers are conducting a randomized, double-blind, placebo-controlled phase II study evaluating Bekinda's safety and efficacy in 127 patients with IBS-D.
2. Researchers enrolled patients in a randomized 60 to 40 ratio to receive either Bekinda or a placebo treatment, once-daily for eight weeks. Researchers are measuring stool consistency as compared to baseline.
3. RedHill expects results in the third quarter of fiscal year 2017. RedHill is also conducting a similar study with Bekinda 24 mg. The company expects results for that study in the second quarter of fiscal year 2017 second quarter.